A 54-year-old woman was referred to our hospital with well differentiated adenocarcinoma of the left lung and multiple metastases to both lungs. On November 7, 1991 Three courses of chemotherapy were given, but the metastases showed no response. Thus, more than three years after the initiation of chemotherapy, the patient is alive with brain metastases and there has been no relapse of the lung tumor.
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The incidence of lung cancer is increasing in Japan. Over 80% of the patients have non-small cell lung cancer (NSCLC), and the majority have inoperable disease at the time of diagnosis. Systemic chemotherapy is an important modality in the treatment of advanced NSCLC. Although cisplatin-containing combination chemotherapy is widely used for NSCLC, it has been difficult to determine whether patients receiving such chemotherapy show improved survival or not.
In this report, we present a NSCLC patient with multiple lung metastases, who has survived more than three years from the start of cisplatin-based chemotherapy. No other metastases were detected by systemic survey. Therefore, the patient was diagnosed as having primary lung cancer of the left upper lobe with bilateral multiple lung metastases, and the clinical stage was IV (T2N2M1), according to the TNM staging system of the UICC.
Chemotherapy consisting of cisplatin (80mg/m2) and adriamycin (30mg/m2) administered intravenously on day 1, plus vindesine (3mg/m2) administered intravenously on days 1 and 8, was started on November 7. Two courses were given with a four-week interval between them. CT of the thorax on January 6, 1992 showed that all the metastatic nodules had disappeared and the primary tumor had
The patient thus showed a complete response of the metastatic lesions, while the primary tumor showed a partial response. On January 13, four weeks after completion of the two courses of chemotherapy, she underwent thoracotomy.
No metastatic nodules were identified in the left lung, and the residual primary tumor was removed by partial pneumonectomy. Histologic examination of the resected tumor revealed degeneration of carcinoma, with a moderate stromal granulomatous reaction and many degraded tumor cells containing pyknotic nuclei (Fig. 3) . Following surgery, five more courses of chemotherapy were given until July 1992, and then 5-fluorouracil was given orally at a daily dose of 200mg for 6 months. In January 1993, the patient complained of severe headache. On February 2, magnetic resonance (MR) imaging of the brain after Gd-DTPA administration showed multiple metastases (Fig. 4A) . The same chemotherapy with cisplatin, adriamycin and vindesine was given again and her severe headache disappeared a few days after the start of treatment. On March 23, two weeks after two courses of chemotherapy, MR imaging of the brain showed that all the metastatic lesions had disappeared, indicating a complete response (Fig.  4B) . Four additional courses of chemotherapy with cisplatin (80mg/m2, day 1) and vindesine (3mg/m2, days 1 and 8)
were given until July 1993. At the beginning of January 1994, she complained of headache again and MR imaging of the brain revealed relapse of brain metastases on January 5.
The duration of remission was 9 months . Three courses of chemotherapy with cisplatin and vindesine were given, but the brain metastases showed no response this time.
After three years and a few months from the initial treatment, the patient is alive with brain metastases, but a In view of these findings, it has been questioned whether use of chemotherapy is justified for the treatment of advanced NSCLC.
Our patient with bilateral lung metastases showed a good response to cisplatin-based chemotherapy, and has now survived for more than three years. As far as we could determine, only 15 cases of metastatic NSCLC with survival for over three years have been reported, including our own (Table 1 ). There were 8 men and 7 women aged from 44 to 80 years. Eleven patients had adenocarcinoma, 3 had squamous cell carcinoma, and one had large cell carcinoma. The lung was the most common metastatic site , being involved in 14 patients. In 10 of these 14 patients, metastatic lesions were not detected clinically and the diagnosis of ipsilateral pulmonary metastasis was made at thoracotomy. Only 4 patients (cases 3,4,5, and the present case) were initially diagnosed as having metastasis to the contralateral lung. Thus, long-term survival with contralateral pulmonary metastasis is extremely rare. to chemotherapy. In the treatment of inoperable NSCLC, we therefore consider that all patients should initially receive a few courses of chemotherapy in order to select the responders who may benefit from prolonged chemotherapy. Furthermore, if these selected patients have a good general condition and can tolerate invasive treatment, adjuvant surgery may be helpful in managing the disease.
